

# PRODUCT INFORMATION



## BAW 2881

Item No. 18910

**CAS Registry No.:** 861875-60-7  
**Formal Name:** 6-[(2-amino-4-pyrimidinyl)oxy]-N-[3-(trifluoromethyl)phenyl]-1-naphthalenecarboxamide

**Synonym:** NVP-BAW 2881

**MF:** C<sub>22</sub>H<sub>15</sub>F<sub>3</sub>N<sub>4</sub>O<sub>2</sub>

**FW:** 424.4


**Purity:** ≥98%

**UV/Vis.:** λ<sub>max</sub>: 226, 284 nm

**Supplied as:** A crystalline solid

**Storage:** -20°C

**Stability:** ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

### Laboratory Procedures

BAW 2881 is supplied as a crystalline solid. A stock solution may be made by dissolving the BAW 2881 in the solvent of choice, which should be purged with an inert gas. BAW 2881 is soluble in organic solvents such as DMSO and dimethyl formamide. The solubility of BAW 2881 in these solvents is approximately 30 mg/ml.

BAW 2881 is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, BAW 2881 should first be dissolved in DMSO and then diluted with the aqueous buffer of choice. BAW 2881 has a solubility of approximately 0.33 mg/ml in a 1:2 solution of DMSO:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

### Description

BAW 2881 is a vascular endothelial growth factor receptor (VEGFR) inhibitor (IC<sub>50</sub>s = 0.82, 0.037, and 0.42 μM for hVEGFR1, 2, and 3, respectively).<sup>1</sup> It inhibits Tie2 and RET with IC<sub>50</sub> values of 0.65 and 0.41 μM, respectively, but demonstrates IC<sub>50</sub> values greater than 10 μM toward a large panel of additional kinases.<sup>1</sup> BAW 2881 was shown to block VEGF-A-induced proliferation, migration, and tube formation of human umbilical vein endothelial cells and lymphatic endothelial cells *in vitro*.<sup>1</sup> In a mouse model of psoriasis, both oral and topical administration of BAW 2881 reduced psoriasis-like inflammation in ear skin.<sup>1</sup> Topical application of BAW 2881 also reduced VEGF-A-induced vascular permeability and inhibited contact hypersensitivity reactions and UV-B-induced erythema in the skin of domestic pigs.<sup>1</sup>

### Reference

1. Halin, C., Fahrngruber, H., Meingassner, J. G., *et al.* Inhibition of chronic and acute skin inflammation by treatment with a vascular endothelial growth factor receptor tyrosine kinase inhibitor. *Am. J. Pathol.* **173**(1), 265-277 (2008).

#### WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

#### SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

#### WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 02/06/2025

#### CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD  
ANN ARBOR, MI 48108 · USA

**PHONE:** [800] 364-9897

[734] 971-3335

**FAX:** [734] 971-3640

CUSTSERV@CAYMANCHEM.COM  
WWW.CAYMANCHEM.COM